ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
5
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,759
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development
Author(s):
A Yver
Publication date:
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Journal of Education and Educational Development
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
1,759
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC)
Authors:
PA Janne
,
SS Ramalingam
,
JC Yang
Preclinical activity of AZD9291 in EGFR-mutant NSCLC brain metastases
Authors:
P. Ballard
,
P Yang
,
D. Cross
…
Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases (BM)
Authors:
D KIM
,
J. Yang
,
D. CROSS
…
See all similar
Cited by
1
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
Authors:
Corey Carter
,
Bryan Oronsky
,
Scott Caroen
…
See all cited by